A Novel Approach to Prostate Cancer Chemotherapy: Design of Prodrugs for Tissue-Specific Activation
Abstract
During the first year of funding, we accomplished the synthesis of three of the four protected Linker-Drug conjugates of doxorubicin and 5-fluorouracil (5-FU) proposed in the original application (Task 1). We have also successfully tested the cyclization activation process of one type of Linker-Drug conjugate of 5-FU (Task 2). Our results established chemically the feasibility of using carbamoyl-5-fluorouracil conjugates as potential prodrugs for the treatment of cancer such as advanced prostate cancer. Some of this work was presented at the 217th national meeting of the American Chemical Society in Anaheim, California. Efforts are now focused on the synthesis of the remaining Linker-Drug conjugate of 5-FU, selective reduction of the nitro and azido group in the conjugates of doxorubicin, and the kinetic analysis of the cyclization activation process.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1999
- Accession Number
- ADB254419
Entities
People
- Longqin Hu
Organizations
- University of Oklahoma Health Sciences Center